Completed PHASE1 INTERVENTIONAL 1-arm NCT01646567

SHP-141C in Plaque Type Psoriasis

A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay.

Sponsor: TetraLogic Pharmaceuticals

Conditions Plaque Type Psoriasis

Interventions Betamethasone Valerate Calcipotriol Placebo to SHP-141C SHP-141C

Updated 5 times since 2017 Last updated: Jul 10, 2014 Started: Sep 30, 2012 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01646567, this PHASE1 trial focuses on Plaque Type Psoriasis and remains completed. Sponsored by TetraLogic Pharmaceuticals, it has been updated 5 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

TetraLogic Pharmaceuticals

Data source: TetraLogic Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia